1. Medtech Insight
  2. >>Business
  3. >>R&D
  4. >>Clinical Trials

Sensus Superficial Radiation Cures 98.9% Of Non-Melanoma Skin Cancer In Study

 
• By Reed Miller

Sensus announced top-line results from a five-year restrospective study of its SRT-100 Superficial Radiation Therapy device for non-melanoma skin cancer. SRT-100 received a 510(k) in 2018.

basal cell carcinoma
basal cell carcinoma • Source: shutterstock.com

A 516-patient retrospective study showed 98.9% of non-melanoma skin cancers treated with Sensus Healthcare Inc.’ SRT-100 low-energy X-ray superficial radiation therapy device were cured five-years after treatment.

In the study, the Kaplan-Meier estimates of cumulative recurrence rates of all tumors at both the two and five-year follow-up were 1.1%. The five-year cumulative recurrence rate for basal cell carcinomas was 1.2%, and 0

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

Medtronic Presents Data To Boost Hugo’s Odds Of Getting FDA Nod

 
• By Brian Bossetta

Medtronic says results from a recent study on the Hugo robotic-assisted surgery system substantiate its safety and effectiveness for various urological procedures. The company also announced it has submitted the system to the FDA for approval for a urological indication.

First Liver Cancer Surveillance Test In Five Years Receives FDA Breakthrough Status

 
• By Natasha Barrow

Cambridge-based startup Mursla Bio's liquid biopsy test EvoLiver uses extracellular vesicles to detect hepatocellular carcinoma (HCC) in high-risk cirrhotic patients. Medtech Insight sat down with with Mursla Bio CEO Pierre Arsène.

Biolinq’s $100M In Series C Financing Supports Efforts To Bring Diabetic Glucose Monitoring With Needle-Free Patch To Market

 
• By Marion Webb

Biolinq plans to use the proceeds of its new venture funding to support US FDA de novo review, automation engineering and commercialization efforts with partners, CEO Rich Yang told Medtech Insight.